Juno's leukemia drug JCAR015 granted FDA 'breakthrough' status
This article was originally published in Scrip
Executive Summary
The FDA has granted breakthrough therapy designation to Juno Therapeutics' chimeric antigen receptor product JCAR015 – a status intended to expedite the regulatory process for the drug.